Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis

Drug Des Devel Ther. 2019 May 16:13:1707-1716. doi: 10.2147/DDDT.S198117. eCollection 2019.


Background: Administration of subcutaneous (SC) bortezomib in patients with multiple myeloma (MM) has increased in recent years. Yet, it is unclear whether there is sufficient evidence to support the use of SC bortezomib as a standard of care. Methods: A systematic review of 4 randomized controlled trials and 8 retrospective trials comparing SC to intravenous (IV) bortezomib among 1,857 MM patients was performed. Embase, PubMed, Clinical, Cochrane Library and reference lists were searched for relevant studies from inception until August 2018. Outcomes of interest included 1-year overall survival (OS), 1-year progression-free survival (PFS), objective response rate (ORR) and adverse events (AEs). Random events meta-analyses were performed. We also performed sensitivity analysis to examine whether the results of the meta-analysis were robust. Results: Compared to IV administration, SC bortezomib had a significantly lower incidence of some all-grade or grade 3-4 AE, such as peripheral sensory neuropathy, leukopenia and thrombocytopenia (p<0.05). There was no statistical difference in 1-year OS, 1-year PFS, ORR between SC and IV bortezomib (p>0.05). Conclusion: The data presented so far consistently show that SC bortezomib has become a standard of care for patients with MM.

Keywords: adverse events; efficacy; intravenous bortezomib; multiple myeloma; subcutaneous bortezomib; systematic review.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Administration, Intravenous
  • Bortezomib / administration & dosage*
  • Bortezomib / therapeutic use*
  • Humans
  • Injections, Subcutaneous
  • Multiple Myeloma / drug therapy*
  • Randomized Controlled Trials as Topic
  • Retrospective Studies
  • Standard of Care*


  • Bortezomib